Ming-Yuan Wang

A dual-targeted, pH-sensitive cationic liposomal system co-delivering paclitaxel and siCXCR2 for synergistic inhibition of lung cancer cells in vitro.

Lung cancer remains the most commonly diagnosed malignancy and a leading cause of cancer-related mortality worldwide. Paclitaxel (PTX), a first-line chemotherapeutic agent for advanced non-small cell lung cancer (NSCLC), is frequently compromised by acquired drug resistance. Here, through network pharmacology analysis...